Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017;7(3):533-543.
doi: 10.3233/JPD-161055.

A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement

Affiliations

A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement

Paul de Roos et al. J Parkinsons Dis. 2017.

Abstract

Background: Parkinson's disease (PD) is a progressive neurodegenerative condition that is expected to double in prevalence due to demographic shifts. Value-based healthcare is a proposed strategy to improve outcomes and decrease costs. To move towards an actual value-based health care system, condition-specific outcomes that are meaningful to patients are essential.

Objective: Propose a global consensus standard set of outcome measures for PD.

Methods: Established methods for outcome measure development were applied, as outlined and used previously by the International Consortium for Health Outcomes Measurement (ICHOM). An international group, representing both patients and experts from the fields of neurology, psychiatry, nursing, and existing outcome measurement efforts, was convened. The group participated in six teleconferences over a six-month period, reviewed existing data and practices, and ultimately proposed a standard set of measures by which patients should be tracked, and how often data should be collected.

Results: The standard set applies to all cases of idiopathic PD, and includes assessments of motor and non-motor symptoms, ability to work, PD-related health status, and hospital admissions. Baseline demographic and clinical variables are included to enable case mix adjustment.

Conclusions: The Standard Set is now ready for use and pilot testing in the clinical setting. Ultimately, we believe that using the set of outcomes proposed here will allow clinicians and scientists across the world to document, report, and compare PD-related outcomes in a standardized fashion. Such international benchmarks will improve our understanding of the disease course and allow for identification of 'best practices', ultimately leading to better informed treatment decisions.

Keywords: Activities of Daily Living; Aged; Delivery of Health Care*/economics; Delivery of Health Care*/standards; Disability Evaluation; Disease Progression; Efficiency; Female; Health Care Costs Health Status; Health Care/standards; Health Surveys; Health Surveys/Health Status Indicators; Humans; International Cooperation; Male; Middle Aged; Organizational; Outcome Assessment (Health Care); Outcome and Process Assessment (Health Care)/standards; Parkinson Disease; Parkinson Disease/epidemiology; Parkinson Disease/therapy*; Parkinsonian Disorders; Psychometrics; Quality Indicators; Quality of Health Care; Quality of Life.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

No conflicts of interest to report: De Roos, Martinez Martin, Antonini, Ray Chaudhuri, Uitti, Wilson, Hagell, Weintraub, Mehta, Marras, Kelley.

Per Odin has given lectures with honorarium and/or had expert advisor role for the following companies: Abbott/AbbVie, Britannia, Bayer, Lund-beck, Orion Pharma, UCB.

Bas Bloem, See separate file attached.

Richard Dodel, See separate file attached.

References

    1. Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet. 2009;373:2055–2066. - PubMed
    1. Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson’s disease in the United States. Mov Disord. 2013;28:311–318. - PubMed
    1. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jönsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen H-C, Stovner LJ, Vallat J-M, Van den Bergh P, den Bergh PV, van Os J, Vos P, Xu W, Wittchen H-U, Jönsson B, Olesen J. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21:718–779. - PubMed
    1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384–386. - PubMed
    1. Porter ME. What is value in health care? N Engl J Med. 2010:2477–2481. - PubMed